From MALT lymphoma to the CBM signalosome: Three decades of discovery

Cell Cycle

Volumn 10, Issue 15, 2011, Pages 2485-2496

  Rosebeck, Shaun ^a   Rehman, Aasia O ^a   Lucas, Peter C ^b   McAllister Lucas, Linda M ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Atherosclerosis; Bcl10; CARMA1; CARMA3; Chromosomal translocation; Cytogenetics; Inflammation; Lymphoma; MALT1; NF B

Indexed keywords

CELL SURFACE RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LYMPHOCYTE ANTIGEN RECEPTOR; PROTEIN BCL 10; PROTEIN CARMA; PROTEIN MALT1; TUMOR PROTEIN; UNCLASSIFIED DRUG;

B CELL LYMPHOMA; CELL FUNCTION; CHROMOSOME TRANSLOCATION; GENE EXPRESSION REGULATION; GENE TARGETING; HUMAN; LYMPHOCYTE; MARGINAL ZONE LYMPHOMA; MOLECULAR CLONING; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; NONHUMAN; REVIEW; SIGNAL TRANSDUCTION;

EID: 79961108913     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.10.15.16923     Document Type: Review

References (116)

1. Isaacson P, Wright DH. Malignant lymphoma of mucosa-associated lymphoid tissue. A distinctive type of B-cell lymphoma. Cancer 1983; 52:1410-6; PMID: 6193858; DOI: 10.1002/1097-0142(19831015)52:8〈1410:: AIDCNCR2820520813〉3.0.CO;2-3.
2. Isaacson PG, Du MQ. MALT lymphoma: from morphology to molecules. Nat Rev Cancer 2004; 4:644-53; PMID: 15286744; DOI: 10.1038/nrc1409.
3. Wotherspoon AC, Ortiz-Hidalgo C, Falzon MR, Isaacson PG. Helicobacter pylori-associated gastritis and primary B-cell gastric lymphoma. Lancet 1991; 338:1175-6; PMID: 1682595; DOI: 10.1016/0140-6736(91)92035-Z.
4. Hussell T, Isaacson PG, Crabtree JE, Spencer J. Helicobacter pylori-specific tumour-infiltrating T cells provide contact dependent help for the growth of malignant B cells in low-grade gastric lymphoma of mucosa-associated lymphoid tissue. J Pathol 1996; 178:122-7; PMID: 8683376; DOI: 10.1002/(SICI)1096-9896(199602)178:2〈122::AIDPATH486〉3.0.CO;2-D.
5. Wotherspoon AC, Pan LX, Diss TC, Isaacson PG. Cytogenetic study of B-cell lymphoma of mucosa-associated lymphoid tissue. Cancer Genet Cytogenet 1992; 58:35-8; PMID: 1728948; DOI: 10.1016/0165-4608(92)90130-Z.
6. Levine EG, Arthur DC, Machnicki J, Frizzera G, Hurd D, Peterson B, et al. Four new recurring translocations in non-Hodgkin lymphoma. Blood 1989; 74:1796-800; PMID: 2506953.
7. Griffin CA, Zehnbauer BA, Beschorner WE, Ambinder R, Mann R. t(11;18)(q21;q21) is a recurrent chromosome abnormality in small lymphocytic lymphoma. Genes Chromosomes Cancer 1992; 4:153-7; PMID: 1373316; DOI: 10.1002/gcc.2870040209.
8. Horsman D, Gascoyne R, Klasa R, Coupland R. t(11;18)(q21;q21.1): a recurring translocation in lymphomas of mucosa-associated lymphoid tissue (MALT)? Genes Chromosomes Cancer 1992; 4:183-7; PMID: 1373320; DOI: 10.1002/gcc.2870040213.
9. Leroux D, Seite P, Hillion J, Le Marc'hadour F, Pegourie-Bandelier B, Jacob MC, et al. t(11;18) (q21;q21) may delineate a spectrum of diffuse small B-cell lymphoma with extranodal involvement. Genes Chromosomes Cancer 1993; 7:54-6; PMID: 7688556; DOI: 10.1002/gcc.2870070109.
10. Ott G, Katzenberger T, Greiner A, Kalla J, Rosenwald A, Heinrich U, et al. The t(11;18)(q21;q21) chromosome translocation is a frequent and specific aberration in low-grade but not high-grade malignant non-Hodgkin's lymphomas of the mucosa-associated lymphoid tissue (MALT-) type. Cancer Res 1997; 57:3944-8; PMID: 9307277.
11. Auer IA, Gascoyne RD, Connors JM, Cotter FE, Greiner TC, Sanger WG, et al. t(11;18)(q21;q21) is the most common translocation in MALT lymphomas. Ann Oncol 1997; 8:979-85; PMID: 9402171; DOI: 10.1023/A:1008202303666.
12. Dierlamm J, Baens M, Wlodarska I, Stefanova-Ouzounova M, Hernandez JM, Hossfeld DK, et al. The apoptosis inhibitor gene API2 and a novel 18q gene, MLT, are recurrently rearranged in the t(11;18) (q21;q21) associated with mucosa-associated lymphoid tissue lymphomas. Blood 1999; 93:3601-9; PMID: 10339464.
13. Akagi T, Motegi M, Tamura A, Suzuki R, Hosokawa Y, Suzuki H, et al. A novel gene, MALT1 at 18q21, is involved in t(11;18) (q21;q21) found in low-grade B-cell lymphoma of mucosa-associated lymphoid tissue. Oncogene 1999; 18:5785-94; PMID: 10523859; DOI: 10.1038/sj.onc.1203018.
14. Morgan JA, Yin Y, Borowsky AD, Kuo F, Nourmand N, Koontz JI, et al. Breakpoints of the t(11;18) (q21;q21) in mucosa-associated lymphoid tissue (MALT) lymphoma lie within or near the previously undescribed gene MALT1 in chromosome 18. Cancer Res 1999; 59:6205-13; PMID: 10626814.
15. Remstein ED, James CD, Kurtin PJ. Incidence and subtype specificity of API2-MALT1 fusion translocations in extranodal, nodal and splenic marginal zone lymphomas. Am J Pathol 2000; 156:1183-8; PMID: 10751343; DOI: 10.1016/S0002-9440(10)64988-7.
16. Baens M, Maes B, Steyls A, Geboes K, Marynen P, De Wolf-Peeters C. The product of the t(11;18), an API2-MLT fusion, marks nearly half of gastric MALT type lymphomas without large cell proliferation. Am J Pathol 2000; 156:1433-9; PMID: 10751367; DOI: 10.1016/S0002-9440(10)65012-2.
17. Maes B, Baens M, Marynen P, De Wolf-Peeters C. The product of the t(11;18), an API2-MLT fusion, is an almost exclusive finding in marginal zone cell lymphoma of extranodal MALT-type. Ann Oncol 2000; 11:521-6; PMID: 10907943; DOI: 10.1023/A:1008357314157.
18. Liu H, Ye H, Dogan A, Ranaldi R, Hamoudi RA, Bearzi I, et al. t(11;18)(q21;q21) is associated with advanced mucosa-associated lymphoid tissue lymphoma that expresses nuclear BCL10. Blood 2001; 98:1182-7; PMID: 11493468; DOI: 10.1182/blood.V98.4.1182.
19. Liu H, Ruskon-Fourmestraux A, Lavergne-Slove A, Ye H, Molina T, Bouhnik Y, et al. Resistance of t(11;18) positive gastric mucosa-associated lymphoid tissue lymphoma to Helicobacter pylori eradication therapy. Lancet 2001; 357:39-40; PMID: 11197361; DOI: 10.1016/S0140-6736(00)03571-6.
20. Liu H, Ye H, Ruskone-Fourmestraux A, De Jong D, Pileri S, Thiede C, et al. t(11;18) is a marker for all stage gastric MALT lymphomas that will not respond to H. pylori eradication. Gastroenterology 2002; 122:1286-94; PMID: 11984515; DOI: 10.1053/gast.2002.33047.
21. Thieblemont C, Berger F, Dumontet C, Moullet I, Bouafia F, Felman P, et al. Mucosa-associated lymphoid tissue lymphoma is a disseminated disease in one third of 158 patients analyzed. Blood 2000; 95:802-6; PMID: 10648389.
22. Wotherspoon AC, Soosay GN, Diss TC, Isaacson PG. Low-grade primary B-cell lymphoma of the lung. An immunohistochemical, molecular and cytogenetic study of a single case. Am J Clin Pathol 1990; 94:655-60; PMID: 2146874.
23. Willis TG, Jadayel DM, Du MQ, Peng H, Perry AR, Abdul-Rauf M, et al. Bcl10 is involved in t(1;14) (p22;q32) of MALT B cell lymphoma and mutated in multiple tumor types. Cell 1999; 96:35-45; PMID: 9989495; DOI: 10.1016/S0092-8674(00)80957-5.
24. Zhang Q, Siebert R, Yan M, Hinzmann B, Cui X, Xue L, et al. Inactivating mutations and overexpression of BCL10, a caspase recruitment domain- containing gene, in MALT lymphoma with t(1;14)(p22;q32). Nat Genet 1999; 22:63-8; PMID: 10319863; DOI: 10.1038/8767.
25. Gill S, Broni J, Jefferies S, Osin P, Kovacs G, Maitland NJ, et al. BCL10 is rarely mutated in human prostate carcinoma, small-cell lung cancer, head and neck tumours, renal carcinoma and sarcomas. MPT Collaborators, St. George's Hospital Collaborators. Br J Cancer 1999; 80:1565-8; PMID: 10408398; DOI: 10.1038/sj.bjc.6690561.
26. Streubel B, Lamprecht A, Dierlamm J, Cerroni L, Stolte M, Ott G, et al. t(14;18)(q32;q21) involving IGH and MALT1 is a frequent chromosomal aberration in MALT lymphoma. Blood 2003; 101:2335-9; PMID: 12406890; DOI: 10.1182/blood-2002-09-2963.
27. Remstein ED, Kurtin PJ, Einerson RR, Paternoster SF, Dewald GW. Primary pulmonary MALT lymphomas show frequent and heterogeneous cytogenetic abnormalities, including aneuploidy and translocations involving API2 and MALT1 and IGH and MALT1. Leukemia 2004; 18:156-60; PMID: 14574335; DOI: 10.1038/sj.leu.2403185.
28. Murga Penas EM, Hinz K, Roser K, Copie-Bergman C, Wlodarska I, Marynen P, et al. Translocations t(11;18)(q21;q21) and t(14;18)(q32;q21) are the main chromosomal abnormalities involving MLT/MALT1 in MALT lymphomas. Leukemia 2003; 17:2225-9; PMID: 12931213; DOI: 10.1038/sj.leu.2403122.
29. Streubel B, Vinatzer U, Lamprecht A, Raderer M, Chott AT. (3;14)(p14.1;q32) involving IGH and FOXP1 is a novel recurrent chromosomal aberration in MALT lymphoma. Leukemia 2005; 19:652-8; PMID: 15703784.
30. Wlodarska I, Veyt E, De Paepe P, Vandenberghe P, Nooijen P, Theate I, et al. FOXP1, a gene highly expressed in a subset of diffuse large B-cell lymphoma, is recurrently targeted by genomic aberrations. Leukemia 2005; 19:1299-305; PMID: 15944719; DOI: 10.1038/sj.leu.2403813.
31. Vinatzer U, Gollinger M, Mullauer L, Raderer M, Chott A, Streubel B. Mucosa-associated lymphoid tissue lymphoma: novel translocations including rearrangements of ODZ2, JMJD2C and CNN3. Clin Cancer Res 2008; 14:6426-31; PMID: 18927281; DOI: 10.1158/1078-0432.CCR-08-0702.
32. Du MQ. MALT lymphoma: many roads lead to nuclear factor-kappab activation. Histopathology 2011; 58:26-38; PMID: 21261681; DOI: 10.1111/j.1365-2559.2010.03699.x.
33. Li Q, Verma IM. NFkappaB regulation in the immune system. Nat Rev Immunol 2002; 2:725-34; PMID: 12360211; DOI: 10.1038/nri910.
34. Gilmore TD. Introduction to NFkappaB: players, pathways, perspectives. Oncogene 2006; 25:6680-4; PMID: 17072321; DOI: 10.1038/sj.onc.1209954.
35. Uren AG, O'Rourke K, Aravind LA, Pisabarro MT, Seshagiri S, Koonin EV, et al. Identification of paracaspases and metacaspases: two ancient families of caspase-like proteins, one of which plays a key role in MALT lymphoma. Mol Cell 2000; 6:961-7; PMID: 11090634; DOI: 10.1016/S1097- 2765(00)00094-0.
36. Lucas PC, Yonezumi M, Inohara N, McAllister-Lucas LM, Abazeed ME, Chen FF, et al. Bcl10 and MALT1, independent targets of chromosomal translocation in malt lymphoma, cooperate in a novel NFkappaB signaling pathway. J Biol Chem 2001; 276:19012-9; PMID: 11262391; DOI: 10.1074/jbc.M009984200.
37. McAllister-Lucas LM, Inohara N, Lucas PC, Ruland J, Benito A, Li Q, et al. Bimp1, a MAGUK family member linking protein kinase C activation to Bcl10-mediated NFkappaB induction. J Biol Chem 2001; 276:30589-97; PMID: 11387339; DOI: 10.1074/jbc.M103824200.
38. Zhou H, Wertz I, O'Rourke K, Ultsch M, Seshagiri S, Eby M, et al. Bcl10 activates the NFkappaB pathway through ubiquitination of NEMO. Nature 2004; 427:167-71; PMID: 14695475; DOI: 10.1038/nature02273.
39. Sun L, Deng L, Ea CK, Xia ZP, Chen ZJ. The TRAF6 ubiquitin ligase and TAK1 kinase mediate IKK activation by BCL10 and MALT1 in T lymphocytes. Mol Cell 2004; 14:289-301; PMID: 15125833; DOI: 10.1016/S1097-2765(04)00236-9.
40. Oeckinghaus A, Wegener E, Welteke V, Ferch U, Arslan SC, Ruland J, et al. Malt1 ubiquitination triggers NFkappaB signaling upon T-cell activation. EMBO J 2007; 26:4634-45; PMID: 17948050; DOI: 10.1038/sj.emboj.7601897.
41. Lucas PC, Kuffa P, Gu S, Kohrt D, Kim DS, Siu K, et al. A dual role for the API2 moiety in API2-MALT1-dependent NFkappaB activation: heterotypic oligomerization and TRAF2 recruitment. Oncogene 2007; 26:5643-54; PMID: 17334391; DOI: 10.1038/sj.onc.1210342.
42. Zhou H, Du MQ, Dixit VM. Constitutive NFkappaB activation by the t(11;18)(q21;q21) product in MALT lymphoma is linked to deregulated ubiquitin ligase activity. Cancer Cell 2005; 7:425-31; PMID: 15894263; DOI: 10.1016/j.ccr.2005.04.012.
43. Rosebeck S, Madden L, Jin X, Gu S, Apel IJ, Appert A, et al. Cleavage of NIK by the API2-MALT1 fusion oncoprotein leads to noncanonical NFkappaB activation. Science 2011; 331:468-72; PMID: 21273489; DOI: 10.1126/science. 1198946.
44. Ruland J, Duncan GS, Elia A, del Barco Barrantes I, Nguyen L, Plyte S, et al. Bcl10 is a positive regulator of antigen receptor-induced activation of NFkappaB and neural tube closure. Cell 2001; 104:33-42; PMID: 11163238; DOI: 10.1016/S0092-8674(01)00189-1.
45. Xue L, Morris SW, Orihuela C, Tuomanen E, Cui X, Wen R, et al. Defective development and function of Bcl10-deficient follicular, marginal zone and B1 B cells. Nat Immunol 2003; 4:857-65; PMID: 12910267; DOI: 10.1038/ni963.
46. Ruland J, Duncan GS, Wakeham A, Mak TW. Differential requirement for Malt1 in T and B cell antigen receptor signaling. Immunity 2003; 19:749-58; PMID: 14614861; DOI: 10.1016/S1074-7613(03)00293-0.
47. Tusche MW, Ward LA, Vu F, McCarthy D, Quintela-Fandino M, Ruland J, et al. Differential requirement of MALT1 for BAFF-induced outcomes in B cell subsets. J Exp Med 2009; 206:2671-83; PMID: 19917778; DOI: 10.1084/jem.20091802.
48. Ruefli-Brasse AA, French DM, Dixit VM. Regulation of NFkappaB-dependent lymphocyte activation and development by paracaspase. Science 2003; 302:1581-4; PMID: 14576442; DOI: 10.1126/science.1090769.
49. Dufner A, Schamel WW. B cell antigen receptor-induced activation of an IRAK4-dependent signaling pathway revealed by a MALT1-IRAK4 double knockout mouse model. Cell Commun Signal 2011; 9:6; PMID: 21396111; DOI: 10.1186/1478-811X-9-6.
50. Bertin J, Guo Y, Wang L, Srinivasula SM, Jacobson MD, Poyet JL, et al. CARD9 is a novel caspase recruitment domain-containing protein that interacts with BCL10/CLAP and activates NFkappaB. J Biol Chem 2000; 275:41082-6; PMID: 11053425; DOI: 10.1074/jbc.C000726200.
51. Gross O, Gewies A, Finger K, Schafer M, Sparwasser T, Peschel C, et al. Card9 controls a non-TLR signalling pathway for innate anti-fungal immunity. Nature 2006; 442:651-6; PMID: 16862125; DOI: 10.1038/nature04926.
52. Gringhuis SI, Wevers BA, Kaptein TM, van Capel TM, Theelen B, Boekhout T, et al. Selective C-Rel activation via Malt1 controls anti-fungal T(H)- 17 immunity by dectin-1 and dectin-2. PLoS Pathog 2011; 7:1001259; PMID: 21283787; DOI: 10.1371/journal.ppat.1001259.
53. Bertin J, Wang L, Guo Y, Jacobson MD, Poyet JL, Srinivasula SM, et al. CARD11 and CARD14 are novel caspase recruitment domain (CARD)/membrane- associated guanylate kinase (MAGUK) family members that interact with BCL10 and activate NFkappaB. J Biol Chem 2001; 276:11877-82; PMID: 11278692; DOI: 10.1074/jbc.M010512200.
54. Gaide O, Martinon F, Micheau O, Bonnet D, Thome M, Tschopp J. Carma1, a CARD-containing binding partner of Bcl10, induces Bcl10 phosphorylation and NFkappaB activation. FEBS Lett 2001; 496:121-7; PMID: 11356195; DOI: 10.1016/S0014-5793(01)02414-0.
55. Wang L, Guo Y, Huang WJ, Ke X, Poyet JL, Manji GA, et al. Card10 is a novel caspase recruitment domain/membrane-associated guanylate kinase family member that interacts with BCL10 and activates NFkappaB. J Biol Chem 2001; 276:21405-9; PMID: 11259443; DOI: 10.1074/jbc.M102488200.
56. Gaide O, Favier B, Legler DF, Bonnet D, Brissoni B, Valitutti S, et al. CARMA1 is a critical lipid raft-associated regulator of TCR-induced NFkappaB activation. Nat Immunol 2002; 3:836-43; PMID: 12154360; DOI: 10.1038/ni830.
57. Wang D, You Y, Case SM, McAllister-Lucas LM, Wang L, DiStefano PS, et al. A requirement for CARMA1 in TCR-induced NFkappaB activation. Nat Immunol 2002; 3:830-5; PMID: 12154356; DOI: 10.1038/ni824.
58. Pomerantz JL, Denny EM, Baltimore D. CARD11 mediates factor-specific activation of NFkappaB by the T cell receptor complex. EMBO J 2002; 21:5184-94; PMID: 12356734; DOI: 10.1093/emboj/cdf505.
59. Gross O, Grupp C, Steinberg C, Zimmermann S, Strasser D, Hannesschlager N, et al. Multiple ITAMcoupled NK-cell receptors engage the Bcl10/Malt1 complex via Carma1 for NFkappaB and MAPK activation to selectively control cytokine production. Blood 2008; 112:2421-8; PMID: 18192506; DOI: 10.1182/blood-2007-11- 123513.
60. Jun JE, Wilson LE, Vinuesa CG, Lesage S, Blery M, Miosge LA, et al. Identifying the MAGUK protein Carma-1 as a central regulator of humoral immune responses and atopy by genome-wide mouse mutagenesis. Immunity 2003; 18:751-62; PMID: 12818157; DOI: 10.1016/S1074-7613(03)00141-9.
61. Newton K, Dixit VM. Mice lacking the CARD of CARMA1 exhibit defective B lymphocyte development and impaired proliferation of their B and T lymphocytes. Curr Biol 2003; 13:1247-51; PMID: 12867037; DOI: 10.1016/S0960-9822(03)00458-5.
62. Egawa T, Albrecht B, Favier B, Sunshine MJ, Mirchandani K, O'Brien W, et al. Requirement for CARMA1 in antigen receptor-induced NFkappaB activation and lymphocyte proliferation. Curr Biol 2003; 13:1252-8; PMID: 12867038; DOI: 10.1016/S0960-9822(03)00491-3.
63. Hara H, Wada T, Bakal C, Kozieradzki I, Suzuki S, Suzuki N, et al. The MAGUK family protein CARD11 is essential for lymphocyte activation. Immunity 2003; 18:763-75; PMID: 12818158; DOI: 10.1016/S1074-7613(03)00148-1.
64. Wang D, Matsumoto R, You Y, Che T, Lin XY, Gaffen SL, et al. CD3/CD28 costimulation-induced NFkappaB activation is mediated by recruitment of protein kinase C-theta, Bcl10 and IkappaB kinase beta to the immunological synapse through CARMA1. Mol Cell Biol 2004; 24:164-71; PMID: 14673152; DOI: 10.1128/MCB.24.1.164-71.2003.
65. Clements JL, Boerth NJ, Lee JR, Koretzky GA. Integration of T cell receptor-dependent signaling pathways by adapter proteins. Annu Rev Immunol 1999; 17:89-108; PMID: 10358754; DOI: 10.1146/annurev.immunol.17.1.89.
66. Matsumoto R, Wang D, Blonska M, Li H, Kobayashi M, Pappu B, et al. Phosphorylation of CARMA1 plays a critical role in T Cell receptor-mediated NFkappaB activation. Immunity 2005; 23:575-85; PMID: 16356856; DOI: 10.1016/j.immuni.2005.10.007.
67. Lee KY, D'Acquisto F, Hayden MS, Shim JH, Ghosh S. PDK1 nucleates T cell receptor-induced signaling complex for NFkappaB activation. Science 2005; 308:114-8; PMID: 15802604; DOI: 10.1126/science.1107107.
68. Sommer K, Guo B, Pomerantz JL, Bandaranayake AD, Moreno-Garcia ME, Ovechkina YL, et al. Phosphorylation of the CARMA1 linker controls NFkappaB activation. Immunity 2005; 23:561-74; PMID: 16356855; DOI: 10.1016/j.immuni. 2005.09.014.
69. Shinohara H, Maeda S, Watarai H, Kurosaki T. IkappaB kinase beta-induced phosphorylation of CARMA1 contributes to CARMA1 Bcl10 MALT1 complex formation in B cells. J Exp Med 2007; 204:3285-93; PMID: 18086859; DOI: 10.1084/jem. 20070379.
70. Kloo B, Nagel D, Pfeifer M, Grau M, Duwel M, Vincendeau M, et al. Critical role of PI3K signaling for NFkappaB-dependent survival in a subset of activated B-cell-like diffuse large B-cell lymphoma cells. Proc Natl Acad Sci USA 2011; 108:272-7; PMID: 21173233; DOI: 10.1073/pnas.1008969108.
71. Davis RE, Ngo VN, Lenz G, Tolar P, Young RM, Romesser PB, et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature 2010; 463:88-92; PMID: 20054396; DOI: 10.1038/nature08638.
72. Brenner D, Brechmann M, Rohling S, Tapernoux M, Mock T, Winter D, et al. Phosphorylation of CARMA1 by HPK1 is critical for NFkappaB activation in T cells. Proc Natl Acad Sci USA 2009; 106:14508-13; PMID: 19706536; DOI: 10.1073/pnas.0900457106.
73. 2+/calmodulin-dependent protein kinase II is a modulator of CARMA1-mediated NFkappaB activation. Mol Cell Biol 2006; 26:5497-508; PMID: 16809782; DOI: 10.1128/MCB.02469-05.
74. Bidère N, Ngo VN, Lee J, Collins C, Zheng L, Wan F, et al. Casein kinase 1alpha governs antigen-receptor-induced NFkappaB activation and human lymphoma cell survival. Nature 2009; 458:92-6; PMID: 19118383; DOI: 10.1038/nature07613.
75. Eitelhuber AC, Warth S, Schimmack G, Duwel M, Hadian K, Demski K, et al. Dephosphorylation of Carma1 by PP2A negatively regulates T-cell activation. EMBO J 2011; 30:594-605; PMID: 21157432; DOI: 10.1038/emboj.2010.331.
76. 2+/calmodulin-dependent protein kinase II. Mol Immunol 2007; 44:2095-100; PMID: 17052756; DOI: 10.1016/j.molimm.2006.09.012.
77. Oruganti SR, Edin S, Grundstrom C, Grundstrom T. CaMKII targets Bcl10 in T-cell receptor induced activation of NFkappaB. Mol Immunol 2011; 48:1448-60; PMID: 21513986; DOI: 10.1016/j.molimm.2011.03.020.
78. 2+-dependent phosphatase calcineurin controls the formation of the Carma1-Bcl10-Malt1 complex during T cell receptorinduced NFkappaB activation. J Biol Chem 2011; 286:7522-34; PMID: 21199863; DOI: 10.1074/jbc.M110.155895.
79. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403:503-11; PMID: 10676951; DOI: 10.1038/35000501.
80. Bea S, Zettl A, Wright G, Salaverria I, Jehn P, Moreno V, et al. Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction. Blood 2005; 106:3183-90; PMID: 16046532; DOI: 10.1182/blood- 2005-04-1399.
81. Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002; 346:1937-47; PMID: 12075054; DOI: 10.1056/NEJMoa012914.
82. Lenz G, Wright GW, Emre NC, Kohlhammer H, Dave SS, Davis RE, et al. Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci USA 2008; 105:13520-5; PMID: 18765795; DOI: 10.1073/pnas.0804295105.
83. Rosenwald A, Wright G, Leroy K, Yu X, Gaulard P, Gascoyne RD, et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med 2003; 198:851-62; PMID: 12975453; DOI: 10.1084/jem.20031074.
84. Ngo VN, Davis RE, Lamy L, Yu X, Zhao H, Lenz G, et al. A loss-of-function RNA interference screen for molecular targets in cancer. Nature 2006; 441:106-10; PMID: 16572121; DOI: 10.1038/nature04687.
85. Dong G, Chanudet E, Zeng N, Appert A, Chen YW, Au WY, et al. A20, ABIN-1/2 and CARD11 mutations and their prognostic value in gastrointestinal diffuse large B-cell lymphoma. Clin Cancer Res 2011; 17:1440-51; PMID: 21266526; DOI: 10.1158/1078-0432.CCR-10-1859.
86. Lenz G, Davis RE, Ngo VN, Lam L, George TC, Wright GW, et al. Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. Science 2008; 319:1676-9; PMID: 18323416; DOI: 10.1126/science.1153629.
87. Lamason RL, McCully RR, Lew SM, Pomerantz JL. Oncogenic CARD11 mutations induce hyperactive signaling by disrupting autoinhibition by the PKC-responsive inhibitory domain. Biochemistry 2010; 49:8240-50; PMID: 20799731; DOI: 10.1021/bi101052d.
88. Blonska M, Lin X. NFkappaB signaling pathways regulated by CARMA family of scaffold proteins. Cell Res 2011; 21:55-70; PMID: 21187856; DOI: 10.1038/cr.2010.182.
89. Grabiner BC, Blonska M, Lin PC, You Y, Wang D, Sun J, et al. CARMA3 deficiency abrogates G protein-coupled receptor-induced NF-{kappa}B activation. Genes Dev 2007; 21:984-96; PMID: 17438001; DOI: 10.1101/gad.1502507.
90. Klemm S, Zimmermann S, Peschel C, Mak TW, Ruland J. Bcl10 and Malt1 control lysophosphatidic acid-induced NFkappaB activation and cytokine production. Proc Natl Acad Sci USA 2007; 104:134-8; PMID: 17095601; DOI: 10.1073/pnas.0608388103.
91. McAllister-Lucas LM, Ruland J, Siu K, Jin X, Gu S, Kim DS, et al. CARMA3/Bcl10/MALT1-dependent NFkappaB activation mediates angiotensin II- responsive inflammatory signaling in nonimmune cells. Proc Natl Acad Sci USA 2007; 104:139-44; PMID: 17101977; DOI: 10.1073/pnas.0601947103.
92. Wang D, You Y, Lin PC, Xue L, Morris SW, Zeng H, et al. Bcl10 plays a critical role in NFkappaB activation induced by G protein-coupled receptors. Proc Natl Acad Sci USA 2007; 104:145-50; PMID: 17179215; DOI: 10.1073/pnas.0601894104.
93. Delekta PC, Apel IJ, Gu S, Siu K, Hattori Y, McAllister-Lucas LM, et al. Thrombin-dependent NF-{kappa} B activation and monocyte/endothelial adhesion are mediated by the CARMA3.Bcl10.MALT1 signalosome. J Biol Chem 2010; 285:41432-42; PMID: 21041303; DOI: 10.1074/jbc.M110.158949.
94. Martin D, Galisteo R, Gutkind JS. CXCL8/IL8 stimulates vascular endothelial growth factor (VEGF) expression and the autocrine activation of VEGFR2 in endothelial cells by activating NFkappaB through the CBM (Carma3/Bcl10/Malt1) complex. J Biol Chem 2009; 284:6038-42; PMID: 19112107; DOI: 10.1074/jbc.C800207200.
95. Rehman AO, Wang CY. CXCL12/SDF-1 alpha activates NFkappaB and promotes oral cancer invasion through the Carma3/Bcl10/Malt1 complex. Int J Oral Sci 2009; 1:105-18; PMID: 20695076; DOI: 10.4248/IJOS.09059.
96. Medoff BD, Landry AL, Wittbold KA, Sandall BP, Derby MC, Cao Z, et al. CARMA3 mediates lysophosphatidic acid-stimulated cytokine secretion by bronchial epithelial cells. Am J Respir Cell Mol Biol 2009; 40:286-94; PMID: 18757306; DOI: 10.1165/rcmb.2008-0129OC.
97. Borthakur A, Bhattacharyya S, Alrefai WA, Tobacman JK, Ramaswamy K, Dudeja PK. Platelet-activating factor-induced NFkappaB activation and IL-8 production in intestinal epithelial cells are Bcl10-dependent. Inflamm Bowel Dis 2010; 16:593-603; PMID: 19714753.
98. McAllister-Lucas LM, Jin X, Gu S, Siu K, McDonnell S, Ruland J, et al. The CARMA3-Bcl10-MALT1 signalosome promotes angiotensin II-dependent vascular inflammation and atherogenesis. J Biol Chem 2010; 285:25880-4; PMID: 20605784; DOI: 10.1074/jbc.C110.109421.
99. Mahanivong C, Chen HM, Yee SW, Pan ZK, Dong Z, Huang S. Protein kinase C alpha-CARMA3 signaling axis links Ras to NFkappaB for lysophosphatidic acid-induced urokinase plasminogen activator expression in ovarian cancer cells. Oncogene 2008; 27:1273-80; PMID: 17724468; DOI: 10.1038/sj.onc.1210746.
100. Jiang T, Grabiner B, Zhu Y, Jiang C, Li H, You Y, et al. CARMA3 is crucial for EGFR-Induced activation of NFkappaB and tumor progression. Cancer Res 2011; 71:2183-92; PMID: 21406399; DOI: 10.1158/0008-5472.CAN-10-3626.
101. Delcourt N, Bockaert J, Marin P. GPCR-jacking: from a new route in RTK signalling to a new concept in GPCR activation. Trends Pharmacol Sci 2007; 28:602-7; PMID: 18001849; DOI: 10.1016/j.tips.2007.09.007.
102. Kasina S, Scherle PA, Hall CL, Macoska JA. ADAM-mediated amphiregulin shedding and EGFR transactivation. Cell Prolif 2009; 42:799-812; PMID: 19735466; DOI: 10.1111/j.1365-2184.2009.00645.x.
103. Porcile C, Bajetto A, Barbero S, Pirani P, Schettini G. CXCR4 activation induces epidermal growth factor receptor transactivation in an ovarian cancer cell line. Ann NY Acad Sci 2004; 1030:162-9; PMID: 15659794; DOI: 10.1196/annals.1329.021.
104. Coornaert B, Baens M, Heyninck K, Bekaert T, Haegman M, Staal J, et al. T cell antigen receptor stimulation induces MALT1 paracaspase- mediated cleavage of the NFkappaB inhibitor A20. Nat Immunol 2008; 9:263-71; PMID: 18223652; DOI: 10.1038/ni1561.
105. Rebeaud F, Hailfinger S, Posevitz-Fejfar A, Tapernoux M, Moser R, Rueda D, et al. The proteolytic activity of the paracaspase MALT1 is key in T cell activation. Nat Immunol 2008; 9:272-81; PMID: 18264101; DOI: 10.1038/ni1568.
106. Malinverni C, Unterreiner A, Staal J, Demeyer A, Galaup M, Luyten M, et al. Cleavage by MALT1 induces cytosolic release of A20. Biochem Biophys Res Commun 2010; 400:543-7; PMID: 20804738; DOI: 10.1016/j.bbrc.2010.08.091.
107. Compagno M, Lim WK, Grunn A, Nandula SV, Brahmachary M, Shen Q, et al. Mutations of multiple genes cause deregulation of NFkappaB in diffuse large B-cell lymphoma. Nature 2009; 459:717-21; PMID: 19412164; DOI: 10.1038/nature07968.
108. Honma K, Tsuzuki S, Nakagawa M, Tagawa H, Nakamura S, Morishima Y, et al. TNFAIP3/A20 functions as a novel tumor suppressor gene in several subtypes of non-Hodgkin lymphomas. Blood 2009; 114:2467-75; PMID: 19608751; DOI: 10.1182/blood-2008-12-194852.
109. Brummelkamp TR, Nijman SM, Dirac AM, Bernards R. Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NFkappaB. Nature 2003; 424:797-801; PMID: 12917690; DOI: 10.1038/nature01811.
110. Sun SC. CYLD: a tumor suppressor deubiquitinase regulating NFkappaB activation and diverse biological processes. Cell Death Differ 2010; 17:25-34; PMID: 19373246; DOI: 10.1038/cdd.2009.43.
111. Staal J, Driege Y, Bekaert T, Demeyer A, Muyllaert D, Van Damme P, et al. T-cell receptor-induced JNK activation requires proteolytic inactivation of CYLD by MALT1. EMBO J 2011; 30:1742-52; PMID: 21448133; DOI: 10.1038/emboj.2011.85.
112. Robertson MJ, Kahl BS, Vose JM, de Vos S, Laughlin M, Flynn PJ, et al. Phase II study of enzastaurin, a protein kinase Cbeta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol 2007; 25:1741-6; PMID: 17389337; DOI: 10.1200/JCO.2006.09.3146.
113. Ferch U, Kloo B, Gewies A, Pfander V, Duwel M, Peschel C, et al. Inhibition of MALT1 protease activity is selectively toxic for activated B cell-like diffuse large B cell lymphoma cells. J Exp Med 2009; 206:2313-20; PMID: 19841089; DOI: 10.1084/jem.20091167.
114. Hailfinger S, Lenz G, Ngo V, Posvitz-Fejfar A, Rebeaud F, Guzzardi M, et al. Essential role of MALT1 protease activity in activated B cell-like diffuse large B-cell lymphoma. Proc Natl Acad Sci USA 2009; 106:19946-51; PMID: 19897720.
115. Hara H, Ishihara C, Takeuchi A, Imanishi T, Xue L, Morris SW, et al. The adaptor protein CARD9 is essential for the activation of myeloid cells through ITAM-associated and Toll-like receptors. Nat Immunol 2007; 8:619-29; PMID: 17486093; DOI: 10.1038/ni1466.
116. Yamasaki S, Ishikawa E, Sakuma M, Hara H, Ogata K, Saito T. Mincle is an ITAM-coupled activating receptor that senses damaged cells. Nat Immunol 2008; 9:1179-88; PMID: 18776906; DOI: 10.1038/ni.1651.